TY - JOUR T1 - “Safety and efficacy of Pulmonary physiotherapy in hospitalized patients with severe COVID-19 pneumonia (PPTCOVID): A prospective, randomised, single-blind, controlled trial” JF - medRxiv DO - 10.1101/2021.04.24.21255892 SP - 2021.04.24.21255892 AU - Mohammad Javaherian AU - Azadeh Shadmehr AU - Abbasali Keshtkar AU - Mohammad Taghi Beigmohammadi AU - Narges Dabbaghipour AU - Aabis Syed AU - Behrouz Attarbashi Moghaddam Y1 - 2021/01/01 UR - http://medrxiv.org/content/early/2021/04/25/2021.04.24.21255892.abstract N2 - Background Pulmonary physiotherapy (PPT) is an important therapeutic tool in the management of patients with different types of pulmonary disorders. We aimed to evaluate safety and efficacy of PPT in hospitalized patients with severe COVID-19 pneumonia.Methods In this randomised, single-blind, controlled trial, we enrolled hospitalized, non-intubated patients (18 to 75 years with oxygen saturation(Spo2) in free-air breathing ≤90%) with COVID-19 pneumonia at a referral hospital. Participants were randomly assigned(1:1) to receive PPT (six sessions PPT with breathing exercises and airway clearance techniques) or basic care. The primary outcomes were venous blood O2(pO2) and CO2(pCO2) pressures, Spo2, and three-minute walking test(3MWT) that were assessed before and end of sixth session. Secondary outcomes included level of dyspnea, venous blood PH, one-month mortality, three-month mortality and short form-36 (SF-36) after one and three months. The assessor was blinded to the assignment. This trial is registered with ClinicalTrials.gov(NCT04357340).Findings In April 2020, 40 participants were randomly assigned to PPT or basic care groups. At the end of intervention, pO2mortality rates wererence to baseline measure(AMD) 6.43mmHg [95%CI 2.8,10.07],P<0.0001), pCO2(AMD -2.1mmHg [95%CI-6.36,2.21],P=0.0011), Spo2(AMD 4.43% [95%CI 2.04,6.83],P=0.0011), and 3MTW (AMD 91.44m [95%CI 68.88,113.99],P<0.0001) were different between groups. While the mortality rate was not different at one month, at three months it was 25% lower in the PPT group (P=.05). This result needs to be reviewed overall though within the manuscript as it is also reported as insignificant “after considering baseline Spo2 as a covariate: OR=.16 [.26,1.05], P=.07;table 4). There were no significant difference in all SF-36 domains scores between groups after one and three months except body pain domain which was higher in PPT group than basic group significantly(P=.01). No serious adverse event was observed during PPT sessions.Conclusion Early PPT can be considered as a safe and effective therapeutic choice for patients with severe COVID-19.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT04357340Funding StatementThis study was funded by the Tehran University of Medical Sciences. The founder of the study had no role in study design, data collection, analysis, interpretation, or writing the manuscript. The corresponding author had full access to all the data in the study and is responsible for publishing the results.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical Committee of Imam Khomeini Hospital Complex, Tehran University of Medical SciencesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll individual participant data that underline the results reported in this article, after de-identification (text, tables, figures, and appendices), statistical analysis plan and Informed consent form are available from the corresponding author and Mohammad Javaherian (Email: Javaherian_m@razi.tums.ac.ir) for researchers who provide a related approved proposal and ethical committee approve to achieve aims. Patient-level information will be anonymised and study documents will be redacted to protect the privacy of trial patients. These data will be available with publication date until one year. ER -